Browse MLKL

Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell membrane Note=Localizes to the cytoplasm and translocates to the plasma membrane on necroptosis induction.
Domain PF07714 Protein tyrosine kinase
Function

Pseudokinase that plays a key role in TNF-induced necroptosis, a programmed cell death process. Activated following phosphorylation by RIPK3, leading to homotrimerization, localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage. Does not have protein kinase activity.

> Gene Ontology
 
Biological Process GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0070206 protein trimerization
GO:0070207 protein homotrimerization
GO:0070265 necrotic cell death
GO:0070266 necroptotic process
GO:0097300 programmed necrotic cell death
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04668 TNF signaling pathway
Reactome R-HSA-5357801: Programmed Cell Death
R-HSA-5213460: RIPK1-mediated regulated necrosis
R-HSA-5218859: Regulated Necrosis
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MLKL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MLKL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MLKL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7130.0196
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3830.738
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9510.231
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3810.19
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7440.644
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0780.97
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1780.657
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2560.815
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1360.906
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7830.538
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9550.614
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1760.0687
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MLKL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MLKL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MLKL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MLKL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MLKL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MLKL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MLKL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMLKL
Namemixed lineage kinase domain-like
Aliases FLJ34389; hMLKL; Mixed lineage kinase domain-like protein
Chromosomal Location16q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MLKL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.